Possible Benefit Found for Betrixaban in Acutely Ill

This article originally appeared here.
Share this content:
Possible Benefit Found for Betrixaban in Acutely Ill
Possible Benefit Found for Betrixaban in Acutely Ill

TUESDAY, May 31, 2016 (HealthDay News) -- Betrixaban may be beneficial versus enoxaparin in acutely ill medical patients, according to a study published online May 27 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee, held from May 25 to 28 in Montpellier, France.

Alexander T. Cohen, M.D., from Guy's and St. Thomas' Hospitals in London, and colleagues randomized 7,513 patients who were hospitalized for acute medical illnesses to either subcutaneous enoxaparin plus oral betrixaban placebo or subcutaneous enoxaparin placebo plus oral betrixaban. Analyses were performed in three prespecified cohorts: patients with an elevated D-dimer level (cohort 1), patients with an elevated D-dimer level or an age of ≥75 years (cohort 2), and all enrolled patients (overall population cohort).

The researchers found that the primary efficacy outcome (a composite of asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembolism) occurred in 6.9 percent of patients receiving betrixaban and 8.5 percent receiving enoxaparin in cohort 1 (relative risk, 0.81; 95 percent confidence interval [CI], 0.65 to 1.00; P = 0.054). In cohort 2 and the overall population cohort the rates were 5.6 and 7.1 percent (relative risk, 0.80; 95 percent CI, 0.66 to 0.98; P = 0.03) and 5.3 and 7.0 percent (relative risk, 0.76; 95 percent CI, 0.63 to 0.92; P = 0.006), respectively.

"Prespecified exploratory analyses provided evidence suggesting a benefit for betrixaban in the two larger cohorts," the authors write.

Several authors were employees of Portola Pharmaceuticals, which manufactures betrixaban and funded the study.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »